AGIO
Agios Pharmaceuticals, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 1.91M | $63.34M | n/a | −1 |
| Q2 2026 | 89 | +3 | 38.62M | $1.43B | +11 | −8 |
| Q1 2026 | 89 | 0 | 33.63M | $1.14B | +5 | −5 |
| Q4 2025 | 89 | -2 | 38.17M | $1.04B | n/a | −2 |
| Q3 2025 | 19 | +2 | 22.49M | $902.53M | +2 | −1 |
| Q2 2025 | 15 | 0 | 21.02M | $699.20M | n/a | n/a |
| Q1 2025 | 12 | -1 | 9.99M | $292.81M | n/a | −1 |
| Q4 2024 | 13 | +2 | 10.10M | $332.03M | +2 | n/a |
| Q3 2024 | 10 | 0 | 7.27M | $323.20M | n/a | n/a |
| Q2 2024 | 10 | n/a | 7.12M | $306.93M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 1.89M | +807.3% | $62.72M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 19.21K | +7.0% | $613,119 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Assetmark, Inc | $48,874 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 231 holders, 62.89M shares, $1.99B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 500 sh · $18,760
Officer · 1.49K sh · $55,882
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology